---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-005294"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:19:18.484689+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearside reports positive safety results from OASIS Phase 1/2a trial of CLS-AX for wet AMD; dose escalation to 0.5 mg

## Summary
- Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.
- Combined Cohorts 1 & 2 (n=11): 36% of patients had no retreatments for ≥3 months; 55% for ≥2 months.
- Mean best corrected visual acuity (BCVA) and central subfield thickness (CST) were stable in the first two cohorts.
- Safety Monitoring Committee approved escalation to Cohort 3 (0.5 mg CLS-AX); patient screening has begun.

## SEC filing metadata
- accession: 0000950170-21-005294
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/0000950170-21-005294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/clsd-20211221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-005294
- JSON: https://secwatch.observer/filing/0000950170-21-005294.json
- Plain text: https://secwatch.observer/filing/0000950170-21-005294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.